Reference is made to the stock exchange announcement from SoftOx Solutions AS
(the "Company") on 16 February 2021 regarding the commencement of the
subscription period in the subsequent offering of up to 181,818 new shares at a
subscription price of NOK 55 per offer share directed towards eligible
shareholders as of 16 December 2020 (as registered in the VPS on 18 December
2020) who did not participate in the private placement successfully completed on
the 16 December 2020 (the "Subsequent Offering").

The subscription period for the Subsequent Offering expired at 16:30 hours
(CEST) today, 3 March 2021. Preliminary counting indicates that the Company has
received subscriptions for approximately 971 404 offer shares. 
The final allocation of the offer shares is expected to take place on or about 4
March 2021, in accordance with the allocation criteria set out in the national
prospectus. 

The final results of the Subsequent Offering will be published shortly after
allocation, and letters with allocation information including subscription
amount to be paid by each subscriber are expected to be distributed during the
course of 4 March 2021.

The payment date for the offer shares allocated in the Subsequent Offering is 8
March 2021, and the delivery date for such shares is expected to be on or about
15 March 2021. The offer shares allocated in the Subsequent Offering are
expected to be tradeable on Euronext Growth Oslo on or about 16 March 2021.

SpareBank 1 Markets AS has acted as Manager and Advokatfirmaet Wiersholm AS has
acted as legal advisor to as the Company in connection with the Subsequent
Offering.

For further information, please contact: 
Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, FM of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS 
SoftOx Solutions AS (SoftOx, listed on the Oslo Stock Exchange Euronext Growth)
is a Norwegian MedTech company based in Oslo with the aim of helping to combat
major threats to human health, namely the emergence of antimicrobial resistance
(AMR), biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com